Valeant Pharmaceuticals has acquired Obagi Cosmeceuticals for $190.0 million. This transaction sees Valeant, a diversified pharmaceutical company, take ownership of Obagi, a specialty pharmaceutical company known for its proprietary topical aesthetic and therapeutic clinically-proven skin care systems. Obagi is a leading provider in the physician-dispensed market, with its foundation dating back to 1988 and officially commencing operations as Obagi Medical in 1997.
The acquisition is strategically significant for Valeant, expanding its presence within the dermatology and aesthetic markets. Obagi's product portfolio is designed to prevent and improve common and visible skin disorders, including photodamage, hyperpigmentation, acne vulgaris, and sun damage. These clinically-proven systems, such as the foundational Obagi Nu-Derm® System, are primarily sold through a direct sales force in the United States and internationally via distribution partners in over 42 countries across multiple continents.
Obagi's focus on the dermatology, plastic surgery, and related aesthetic markets aligns with Valeant's broader pharmaceutical interests. The integration of Obagi's established brand and specialized product lines is expected to create synergies, leveraging Valeant's resources and global reach to enhance Obagi's market penetration and product development capabilities. This move strengthens Valeant's offerings to healthcare professionals and patients seeking advanced skin health solutions.
Looking ahead, the combined entity is poised to reinforce Valeant's position in the competitive aesthetic and therapeutic skin care landscape. The acquisition is anticipated to drive continued growth and innovation for Obagi's product lines, ensuring their expanded availability and further development under Valeant's ownership.